Salivary Cytokines in patients with Head and Neck Cancer (HNC) treated with Radiotherapy by Principe, Sara et al.
 J Clin Exp Dent. 2019;11(11):e1072-7.                                                                                                                                                                                 Salivary cytokines in head and neck cancer
e1072
Journal section: Oral Medicine and Pathology                        
Publication Types: Review
Salivary Cytokines in patients with Head and 
Neck Cancer (HNC) treated with Radiotherapy
Sara Principe 1, Valentina Dikova 1, José Bagán 2
1 PhD Candidate, Faculty of Medicine and Dentistry, University of Valencia, Fundación Investigación Hospital General Universi-
tari (FiHgU) Valencia, Spain 
2  Service of Stomatology and Maxillofacial Surgery, Hospital General Universitari de Valencia, Faculty of Medicine and Dentistry, 
University of Valencia, Spain
Correspondence:
Faculty of Medicine and Dentistry
University of Valencia





Background: Head and Neck cancer (HNC) is the sixth most common cancer in the world. The 5-year survival rate 
depends on early diagnosis and appropriate therapy. Typically, late diagnosis requires not only surgical interven-
tion, but also radiotherapy treatment combined or not with chemotherapy. Ionizing radiation is known to increase 
the expression of a number of cytokines involved in inflammation, wound healing and toxicity areas. Salivary 
cytokines have promising features to be used as biomarkers for disease screening and outcome prediction in this 
malignancy. The aim of this article is to analyze the role of salivary inflammatory response elements in HNC pa-
tients treated with radiotherapy, their modulation and association with the treatment outcome. 
Material and Methods: A bibliographical search was performed on Pubmed, Cochrane and Embase using the fo-
llowing keywords: cytokines, saliva, head and neck cancer, radiotherapy. The cut-off point for the research were 
scientific papers published over the last 10 years. After a two-step selection process, 15 articles were identified and 
subjected to review.
Results: Radiotherapy treatment was shown to influence a number of salivary cytokines. A trend towards a growth 
of IL-1β, IL-6, IL-8, MCP-1, and TNF-α levels was observed and it correlated with the irradiation dose.
Conclusions: The analysis of salivary cytokines could be a useful biomarker for predicting radiotherapy outcome 
in HNC. However, large-scale investigations are required to validate the use of these cytokines in predicting and 
diagnosing HNC, as well as evaluating the response to the treatment.




Head and Neck cancer (HNC) is a complex and hetero-
geneous malignancy, encompassing a variety of tumors 
that originate in the hypopharynx, oropharynx, naso-
pharynx, larynx, lips, or oral cavity. The disease group is 
associated with a distinct epidemiology, etiology, and the 
required therapies are also different. Worldwide, it re-
presents the sixth most common neoplasia and accounts 
for 6% of all cases, being responsible for approximately 
1-2% of tumor deaths (1). Despite all the diagnostic and 
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therapeutic advances, the 5-year survival rate of patients 
with HNC remains relatively unfavorable, around 50%. 
Alcohol and tobacco use are among the most common 
risk factors for HNC (2), although high-risk human pa-
pillomavirus (HPVs) infection, especially type 16, has 
been implicated in the pathogenesis of HNC arising 
from the oropharynx (3). Treatment approaches can in-
clude surgery, radiotherapy (RT), chemotherapy (CT), 
targeted therapy or a combination of them. The selection 
of unique or combined modality treatments is based on 
considerations such as disease control probability, an-
ticipated functional outcomes, tumor resection and the 
patient’s general condition (4). Survival and cure benefit 
from early diagnosis and appropriate therapy. However, 
late diagnosis usually requires surgical intervention and 
chemo-radiotherapy treatment.
Ionizing radiation is known to increase the expression of 
a number of cytokines involved in inflammation, wound 
healing and toxicity (5). Cytokines are intercellular sig-
naling proteins that play a role in regulating growth, ce-
llular proliferation, angiogenesis, and tissue repair. They 
also have a function in immune responses to infection, 
injury and inflammation (6). Cytokine levels are genera-
lly kept within a specified range and time; if not properly 
maintained, they can lead to induction of tissue damage. 
Cytokines have also been investigated in saliva as poten-
tial protein biomarkers of HNC (7)(5). In particular, va-
rious inflammatory and angiogenic cytokines have been 
proven to be increased in the saliva of tumor patients (8). 
The most frequently analyzed salivary proteins are 
EGF, interleukin 6 and 8, and to a lesser extent other 
NFκB-derived members such as TNFα or interleukin 
1β, interleukin 4 and 10, and VEGF (9). However, se-
veral oral and systemic conditions, including periodon-
tal disease, Sjögren syndrome, and rheumatoid arthritis 
can also give rise to increased levels of inflammatory 
proteins in saliva (10). Evaluation of tumor and normal 
tissue in irradiated areas using biopsies or invasive tech-
niques for correlative assays may be limited with respect 
to healing during and after therapy. Sampling of saliva 
is feasible and could provide a non-invasive method to 
prove the local effects of ionizing radiation on tumor and 
normal tissue. Salivary cytokines have promising featu-
res to be used as biomarkers for disease screening and 
outcome prediction in this malignancy. 
The majority of saliva studies have focused on relati-
ve levels of cytokines in saliva between HNC patients 
and healthy individuals (7). However, changes in saliva 
from pre- to post-treatment have not been extensively 
explored due to the destruction of salivary glands and 
subsequent xerostomia with conventional radiation. 
This impasse changed with the emergence of salivary 
gland-sparing radiation that allows saliva recovery (11). 
As the use of gland-sparing, intensity-modulated radia-
tion therapy (IMRT) increases, Russo et al. in 2016 (8) 
investigated a panel of cytokines in whole saliva from 
HNC patients, pre- and post-treatment. Even though 
most studies mention elevated concentrations of candi-
date tumor markers in saliva, this is not true for all of 
them, as reductions in peptide expression have also been 
reported (9). Dealing with this, the majority of investi-
gations have targeted EGF. This growth factor not only 
positively influences cell proliferation, but its levels 
also positively correlate with the invasive behavior of 
oral cancer cells. Indirectly, the decrease in EGF during 
and after radiotherapy of head and neck cancer patients 
could be the cause for impaired wound healing in the 
oral cavity and adjacent tissues, due to the fact that the 
salivary glands are often located within the beam pro-
jection (9).
Screening salivary cytokine levels could provide a useful 
approach to the identification of biomarkers for predic-
ting radiotherapy outcomes. When applied to a high-risk 
population such as HNC survivors, a saliva-based test 
utilizing a panel of biomarkers for HNC could provi-
de an accurate, non-invasive and relatively inexpensive 
monitoring method (7).
The aim of this article is to make an overview of salivary 
cytokines modulation and their association with radio-
therapy outcomes in HNC patients. 
Material and Methods
A literature review was performed on scientific articles 
on HNC, salivary cytokines and radiotherapy treatment. 
The research included studies published on Pubmed du-
ring the past 10 years. This was then supplemented by a 
new search using the same key words in the following 
database: Cochrane and Embase. 
The inclusion criteria for selecting articles were as fo-
llows:
- studies that focused on biomarkers for HNC diagnosis 
and/or treatment outcomes related with radiation or che-
moradiation therapy.
- studies that included patients with HNC and OSCC 
(Oral Squamous cell carcinoma).
- studies that used saliva for the analysis of these bio-
markers.
Studies that used different biological media such as 
blood, serum or body fluids instead of saliva as potential 
media diagnostics and/or to monitor HNC patients, and 
also articles that reported associations between saliva 
and cancer in experimental studies (in vitro or in vivo 
animal studies) were excluded.
The references cited in the selected papers were also 
checked for any incremental references that may have 
inadvertently been omitted during the electronic databa-
se searches.
The study selection was accomplished in two phases. 
During the first phase, a selection of the articles that 
appeared to meet the inclusion criteria based on their 
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titles and abstracts was performed. In the second phase, 
full articles were evaluated and the final selection of 15 
papers was based on the full text of the publication.
For all the included articles, the following information 
was recorded: year of publication, author(s), country, 
sample size, patient age, study methods, list of cytokines 
analyzed, and main conclusions.
Results 
The studies were conducted in six different countries: 
mostly in the United States, and the rest in Brazil, Cana-
da, Croatia, Iran and Italy. The salivary cytokines were 
assessed by different methods, the most common being 
the enzyme-linked immunosorbent assay (ELISA), fo-
llowed by the multiplexed immunobead-based assay 
technology. An overview of the summarized data regar-
ding the selected articles is provided in Table 1. 
Bossi et al. in 2016 (12) followed the concentration, 
the modulation and the association of salivary cytoki-
nes with oral mucositis severity in HNC patients sub-
jected to chemoradiation therapy (CTRT). The study 
was a prospective observational study and included 55 
individuals diagnosed with locally advanced HNC. The 
levels of 13 cytokines were quantified before and after 
treatment. Overall increase was observed while the the-
rapy was ongoing, especially in patients with severe mu-
cositis. CTRT seemed to cause a significant growth of 
Interleukin 1β and 6 (IL-1β, IL-6) and tumor necrosis 
factor-α (TNF-α), all positively associated with the se-
verity of mucosal toxicity.
Citrin et al. in 2012 (5), in a pilot study, explored the 
feasibility of using an ophthalmic sponge (Merocel) to 
sample saliva and to evaluate cytokine concentration in 
HNC patients undergoing CTRT. The results support the 
hypothesis that cytokine levels increase during the cour-
se of radiotherapy. Besides, their amounts vary depen-
ding on the proximity to the tumor irradiation area. Sa-
livary levels of IL-4, IL-6, IL-8, EGF, MCP-1, TNF-α, 
and VEGF were found to be augmented in high dose 
radiation region when compared to the low dose one. 
Author, Year Cases Pathology Methods Results
Bossi et al. 
(2016)
55 HNC Multiplexed 
immunobead-based 
assay
CTRT increased the salivary levels of IL-1b, 
IL-6, and TNF-a, all associated with mucosal 
toxicity. A greater increase of IL-1b and IL-6 







A trend towards a growth of IL-6, IL-8, MCP-1 
and TNF-α levels was observed to correlate with 
the irradiation dose.





Secretion of EGF, GROα, IL-1α, IL-1β, IL-6, 
IL-8, TNFα, and VEGF increased significantly 
post-treatment.
Epstain et al. 
(2000)
18 OSCC & HNC Enzyme-linked 
immunosorbent assay 
(ELISA)
EGF decrease was shown during RT, because 




32 OSCC & HNC Enzyme-linked 
immunosorbent assay 
(ELISA)
IL-8 was detected at higher concentrations in 
saliva of patients with OSCC.
Cerovic et al.
(2013)
19,19 Oral Premalignant 
Lesion (OPML) & 
OSCC
Enzyme-linked
 immunosorbent assay 
(ELISA)
Higher salivary concentrations of TNF-α and 
IL-6 were detected in OPML and OSCC group 
compared with healthy controls.
Rhodus et al. 
(2005)
13,13 Oral Premalignant 
Lesion (OPML) & 
OSCC
Enzyme-linked
 immunosorbent assay 
(ELISA)
TNF-a, IL-1a, IL-6, and IL-8 were elevated in 
the whole saliva of subjects with OSCC and 
with OPML.




 immunosorbent assay 
(ELISA)
The concentration of salivary IL-6 in OSCC 
patients was higher than in the control group 
and it was statistically significant (p < 0.05). 
TNF-α, IL-1α and IL-8 levels in the case group 
were higher than in the control group but it was 
not statistically significant.
Table 1: Summary of descriptive characteristics of included studies.
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A trend towards a growth of IL-6, IL-8, MCP-1, and 
TNF-α levels was observed to correlate with the irra-
diation dose. 
Russo et al. in 2016 (8) showed a post-treatment increa-
se in multiple cytokines in stimulated whole saliva from 
patients with HNC. Eight cytokines — TNFα, EGF, 
GROα, IL-1α, IL-1β, IL-6, IL-8, and VEGF — were 
analyzed and quantified concurrently in a multiplex as-
say. GROα, IL-1α, IL-1β, Il-6, IL-8, TNFα, and VEGF 
increased pre- to post-treatment. 
Epstain et al. (13) showed that saliva volume and total 
EGF output decreased significantly in the first weeks of 
RT treatment and remained reduced throughout the the-
rapy. In a previous study by the same author, with 18 
head and neck carcinoma patients, EGF in saliva was 
also shown to decrease during RT due to reduced con-
centration and reduced saliva volume as radiation treat-
ment progressed (14). 
Previous studies have also demonstrated that some 
pro-inflammatory cytokines such as TNF-α , IL-1α, IL-
6, IL-8, granulocyte-macrophage colony-stimulating 
factor receptor (GM-CSF) and VEGF can be found in 
significantly elevated levels in the local environment of 
OSCC (15). 
In 2015 Guerra et al. (16) in their systematic review and 
meta-analysis evaluated the diagnostic value of salivary 
biological markers in the diagnosis of head and neck 
carcinoma. IL-8 was the most commonly assessed bio-
marker, analyzed in five studies. Among these studies, 
St. John et al. (17) obtained the best diagnostic capabili-
ty results. This study reported that IL-8 was detected at 
higher concentrations in the saliva of patients with HNC 
(P < 0.01), and the findings suggest that IL-8 may hold 
promise as a biomarker for oral cancer. 
The study performed by Cerovic et al. in 2013 (18) 
showed that TNF-α and IL-6 cytokines were detected in 
the whole saliva of 57 patients who were examined be-
tween 2008 and 2010 at the Department of Oral Medici-
ne and Department of Oral and Maxillofacial Surgery of 
the Medical Faculty, University of Rijeka, Croatia. They 
were divided into three groups: 19 patients with oral 
premalignant lesions (OPML), 19 with OSCC and 19 
healthy control volunteers. Results proved the patients 
with OPML and OSCC to have higher salivary cytokine 
concentrations compared with healthy controls. 
Rhodus et al. in 2005 (15) reported increased concentra-
tions of salivary IL-6 and TNF-α in oral cancer patients 
and in patients with oral precancerous lesions, while St 
John et al. (17) found no significant differences in sa-
livary IL-6 in oral cancer patients compared to healthy 
controls. 
The pathological activities of TNF-α have attracted 
much attention. For instance, although TNF-α causes 
necrosis in some types of tumors, it promotes growth of 
other types of tumor cells. High levels of TNF-α corre-
late with increased risk of mortality. These results indi-
cate that increased salivary concentrations of TNF-α and 
IL-6 reflect local production of these cytokines in cancer 
tissue (18).
In 2008, SahebJamee et al. (19) confirmed that the con-
centration of salivary IL-6 in oral squamous cell carci-
noma patients was higher than in the control group and it 
was statistically significant (p < 0.05). The concentration 
of salivary TNF-α, interleukin 1α and 8 in the disease 
group was higher than in the control group but it was not 
statistically significant (p > 0.05). These results show 
that more studies are needed to accept the utility of the-
se cytokines in the prediction or diagnosis of oral squa-
mous cell carcinoma and the evaluation of treatment. 
Finally, Sahibzada et al. in 2017 (20) in their review also 
suggested that there is an elevation of IL-6, IL-8, IL-1 
and TNF-α in OSCC and other oral neoplastic lesions 
because of their characteristic features, such as pro-an-
giogenesis and pro-inflammation effect which, in turn, 
has a diagnostic value. 
Discussion
The result of this literature review indicates that radia-
tion or chemoradiation therapy can influence a number 
of salivary cytokines and, consequently, the analysis of 
salivary cytokines could be a useful biomarker for pre-
dicting radiotherapy outcome in HNC. Several studies 
reported increases in salivary IL-8, TNF-α, IL-1, IL-6 in 
HNC compared to controls but did not quantify changes 
post-treatment. A surprising finding observed by Russo 
et al. (8) was the post-treatment increase in cytokines. 
The study quantified cytokines pre- and post-treatment. 
Secretion of IL-1α, IL-1β, IL-6, IL-8, TNFα, and VEGF 
increased significantly post-treatment but EGF showed no 
changes. This may be related to the response to treatment. 
Another factor to be considered is the post-radiation mu-
cositis which correlates with increases in cytokines (14). 
However, IL-6 was increased in patients who received 
surgery alone, suggesting that this increase is related to 
the response to the treatment, not to the radiation-indu-
ced inflammation (8).
The concurrent increase in IL-6 and IL-8 in post-treat-
ment saliva suggests a common regulatory mechanism, 
such as NF-κB, which plays an important role in the de-
velopment and progression of HNC; NF-κB-regulated 
cytokines are upregulated in saliva in HNC (15). The 
activation of pro-inflammatory cytokines plays a key 
role in the development of oral mucositis occurring after 
the first initiation phase, consisting of the generation of 
reactive oxygen species that promotes upregulation of 
messenger signals. One of the most important factors is 
NF-kB, which in turn activates several genes, including 
those linked to the production of the pro-inflammatory 
cytokines (12).
Not only radiotherapy treatment but also CTRT seemed 
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to cause a significant increase in IL-1β, IL-6 and TNF-α, 
all positively associated with the severity of mucosal to-
xicity. This finding suggests that the elevation of these 
cytokines three weeks after therapy initiation could be 
predictive of a more severe oral mucositis. Furthermore, 
it may represent a potential approach for early identifi-
cation of risk patients (12).
In several of the cytokines that Citrin et al. (5) analyzed, 
a trend toward increasing levels with increasing the 
dose delivered was observed for IL-6, IL-8, MCP-1, and 
TNF-α. Subsequent sampling is likely to provide more 
striking differences in the levels of cytokines in saliva 
compared to baseline measurements. To more tissue 
changes such as inflammation and desquamation due to 
higher doses of radiation.
The differential changes observed between different 
cytokines pre- and post-treatment support the idea that 
the variation is not entirely a function of reduced fluid 
content of post-treatment saliva, which would increase 
all cytokines. Moreover, since ionizing radiation increa-
ses expression of pro-inflammatory and proangiogenic 
factors, differences in cytokines between patients treated 
with radiation or surgery were also investigated by Rus-
so et al. (8), suggesting that changes in cytokines did not 
vary as a function of treatment modalities. 
There are limitations to this review that we should hi-
ghlight. Firstly, not all the studies were comparable as 
only some of them were case-control studies. Besides, 
the cytokines were not measured using the same tech-
nique. Secondly, the sample size regarding the levels of 
salivary inflammatory proteins pre- and post-treatment 
was relatively small. A larger sample cohort would 
allow for a greater statistical comparison between the 
two groups.
Conclusions
Radiation alone or in a combination with chemotherapy 
is frequently used in the management of malignancies in 
the head and neck, being the primary treatment option 
for advanced head and neck cancers. Despite the increa-
sing number of studies and reviews concerning salivary 
biomarkers for HNC, there is no consensus regarding 
which biomarker has the best diagnostic value (16). This 
review demonstrates that screening salivary cytokine le-
vels could provide a useful approach to identifying bio-
markers for predicting radiotherapy outcome in HNC. 
However, more studies are needed to verify the utility 
of these proteins in prognosis and diagnosis of HNC and 
as an indicator of the patient’s response to the treatment.
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